<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23837630</article-id><article-id pub-id-type="pmc">3716978</article-id><article-id pub-id-type="publisher-id">1745-6215-14-206</article-id><article-id pub-id-type="doi">10.1186/1745-6215-14-206</article-id><article-categories><subj-group subj-group-type="heading"><subject>Update</subject></subj-group></article-categories><title-group><article-title>Update on the transfusion in gastrointestinal bleeding (TRIGGER) trial: statistical analysis plan for a cluster-randomised feasibility trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Kahan</surname><given-names>Brennan C</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>b.kahan@ucl.ac.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Jairath</surname><given-names>Vipul</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>Vipul.Jairath@nhsbt.nhs.uk</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Murphy</surname><given-names>Michael F</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>mike.murphy@nhsbt.nhs.uk</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Doré</surname><given-names>Caroline J</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>C.Dore@ctu.mrc.ac.uk</email></contrib></contrib-group><aff id="I1"><label>1</label>MRC Clinical Trials Unit, Aviation House 125 Kingsway, London WC2B 6NH, UK</aff><aff id="I2"><label>2</label>NHS Blood &amp; Transplant, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK</aff><aff id="I3"><label>3</label>Translational Gastroenterology Unit, Oxford, UK</aff><aff id="I4"><label>4</label>Transfusion Medicine, Oxford University Hospitals NHS Trust, Oxford, UK</aff><aff id="I5"><label>5</label>University of Oxford, Oxford, UK</aff><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>10</day><month>7</month><year>2013</year></pub-date><volume>14</volume><fpage>206</fpage><lpage>206</lpage><history><date date-type="received"><day>8</day><month>3</month><year>2013</year></date><date date-type="accepted"><day>27</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 Kahan et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Kahan et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.trialsjournal.com/content/14/1/206"></self-uri><abstract><sec><title><offsets xml_i="3696" xml_f="3706" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3717" xml_f="3925" txt_i="22" txt_f="230">Previous research has suggested an association between more liberal red blood cell (RBC) transfusion and greater risk of further bleeding and mortality following acute upper gastrointestinal bleeding (AUGIB).</offsets></p></sec><sec><title><offsets xml_i="3947" xml_f="3965" txt_i="232" txt_f="250">Methods and design</offsets></title><p><offsets xml_i="3976" xml_f="4158" txt_i="251" txt_f="433">The Transfusion in Gastrointestinal Bleeding (TRIGGER) trial is a pragmatic cluster-randomised feasibility trial which aims to evaluate the feasibility of implementing a restrictive </offsets><italic><offsets xml_i="4166" xml_f="4169" txt_i="433" txt_f="436">vs.</offsets></italic><offsets xml_i="4178" xml_f="4785" txt_i="436" txt_f="1043"> liberal RBC transfusion policy for adult patients admitted to hospital with AUGIB in the UK. This trial will help to inform the design and methodology of a phase III trial. The protocol for TRIGGER has been published in Transfusion Medicine Reviews. Recruitment began in September 2012 and was completed in March 2013. This update presents the statistical analysis plan, detailing how analysis of the TRIGGER trial will be performed. It is hoped that prospective publication of the full statistical analysis plan will increase transparency and give readers a clear overview of how TRIGGER will be analysed.</offsets></p></sec><sec><title><offsets xml_i="4807" xml_f="4825" txt_i="1045" txt_f="1063">Trial registration</offsets></title><p><ext-link ext-link-type="uri" xlink:href="http://www.controlled-trials.com/ISRCTN85757829"><offsets xml_i="4927" xml_f="4941" txt_i="1064" txt_f="1078">ISRCTN85757829</offsets></ext-link></p></sec></abstract><kwd-group><kwd>Statistical analysis plan</kwd><kwd>Cluster randomised trial</kwd><kwd>Transfusion</kwd><kwd>Gastrointestinal bleeding</kwd><kwd>Variceal bleeding</kwd><kwd>Feasibility trial</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="5222" xml_f="5228" txt_i="1087" txt_f="1093">Update</offsets></title><sec><title><offsets xml_i="5248" xml_f="5260" txt_i="1094" txt_f="1106">Introduction</offsets></title><p><offsets xml_i="5271" xml_f="5490" txt_i="1107" txt_f="1326">Acute Upper Gastrointestinal Bleeding (AUGIB) is the most common reason for emergency hospital admission with a gastrointestinal disorder in the United Kingdom (UK) with an annual incidence of 50 to 150/100,000 adults [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5521" xml_f="5522" txt_i="1326" txt_f="1327">1</offsets></xref><offsets xml_i="5529" xml_f="5658" txt_i="1327" txt_f="1456">]. It is also the leading indication for red blood cell (RBC) transfusion, accounting for 14% of all RBCs transfused in England [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="5689" xml_f="5690" txt_i="1456" txt_f="1457">2</offsets></xref><offsets xml_i="5697" xml_f="5845" txt_i="1457" txt_f="1605">]. RBC transfusion is commonly based upon the patient’s haemoglobin (Hb) level; however, the optimal Hb threshold at which to transfuse is unclear [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="5876" xml_f="5877" txt_i="1605" txt_f="1606">3</offsets></xref><offsets xml_i="5884" xml_f="5885" txt_i="1606" txt_f="1607">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="5916" xml_f="5917" txt_i="1607" txt_f="1608">4</offsets></xref><offsets xml_i="5924" xml_f="6063" txt_i="1608" txt_f="1747">]. Two observational studies have indicated an association between RBC transfusion after AUGIB and risk of further bleeding and mortality [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="6094" xml_f="6095" txt_i="1747" txt_f="1748">5</offsets></xref><offsets xml_i="6102" xml_f="6103" txt_i="1748" txt_f="1749">,</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="6134" xml_f="6135" txt_i="1749" txt_f="1750">6</offsets></xref><offsets xml_i="6142" xml_f="6262" txt_i="1750" txt_f="1870">]. A recently published randomised trial found a liberal approach to transfusion led to an increased risk of mortality [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="6293" xml_f="6294" txt_i="1870" txt_f="1871">7</offsets></xref><offsets xml_i="6301" xml_f="6499" txt_i="1871" txt_f="2069">], although these results may not be generalisable due to the strict protocols of care implemented in this single centre trial, which are unlikely to be reproducible in most healthcare institutions.</offsets></p><p><offsets xml_i="6506" xml_f="6664" txt_i="2070" txt_f="2228">The Transfusion in Gastrointestinal Bleeding (TRIGGER) trial is a cluster-randomised trial designed to evaluate the feasibility of implementing a restrictive </offsets><italic><offsets xml_i="6672" xml_f="6675" txt_i="2228" txt_f="2231">vs.</offsets></italic><offsets xml_i="6684" xml_f="6762" txt_i="2231" txt_f="2309"> liberal RBC transfusion policy for patients admitted to hospital with AUGIB [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6793" xml_f="6794" txt_i="2309" txt_f="2310">8</offsets></xref><offsets xml_i="6801" xml_f="7455" txt_i="2310" txt_f="2964">]. TRIGGER is a pragmatic trial which aims to reflect real world settings as closely as possible. Six hospitals in the United Kingdom were randomised in a 1:1 ratio to follow either a liberal transfusion policy (where eligible patients are transfused when their Hb drops below 10 g/dL) or a restrictive transfusion policy (where eligible patients are transfused when their Hb drops below 8 g/dL). Randomisation was performed using permuted blocks without stratification or matching, with a block size of six (to ensure three hospitals in each arm). Hospitals were randomised in July 2012, and recruitment took place between September 2012 and March 2013.</offsets></p><p><offsets xml_i="7462" xml_f="7535" txt_i="2965" txt_f="3038">The TRIGGER protocol has been published in Transfusion Medicine Reviews [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="7566" xml_f="7567" txt_i="3038" txt_f="3039">8</offsets></xref><offsets xml_i="7574" xml_f="7590" txt_i="3039" txt_f="3055">] (available at </offsets><ext-link ext-link-type="uri" xlink:href="http://www.tmreviews.com"><offsets xml_i="7658" xml_f="7682" txt_i="3055" txt_f="3079">http://www.tmreviews.com</offsets></ext-link><offsets xml_i="7693" xml_f="7952" txt_i="3079" txt_f="3338">), and gives details on the rationale for the study, the inclusion/exclusion criteria, the sample size calculation and the process for consenting patients to the trial. This update to the published protocol describes the statistical analysis plan for TRIGGER.</offsets></p><p><offsets xml_i="7959" xml_f="8203" txt_i="3339" txt_f="3583">The TRIGGER trial was conducted according to the declaration of Helsinki, and received ethical approval from the Scotland A Research Ethics Committee (Reference 12/SS/0023) and the NRES Committee South Central – Oxford C (Reference 12/SC/0062).</offsets></p></sec><sec><title><offsets xml_i="8225" xml_f="8233" txt_i="3585" txt_f="3593">Outcomes</offsets></title><p><offsets xml_i="8244" xml_f="8375" txt_i="3594" txt_f="3725">This trial will report both feasibility and clinical outcomes. Outcome definitions and explanations are available in the protocol [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="8406" xml_f="8407" txt_i="3725" txt_f="3726">8</offsets></xref><offsets xml_i="8414" xml_f="8416" txt_i="3726" txt_f="3728">].</offsets></p></sec><sec><title><offsets xml_i="8438" xml_f="8458" txt_i="3730" txt_f="3750">Feasibility outcomes</offsets></title><p><offsets xml_i="8469" xml_f="8498" txt_i="3751" txt_f="3780">The feasibility outcomes are:</offsets></p><p><offsets xml_i="8505" xml_f="8562" txt_i="3781" txt_f="3838">• The proportion of eligible patients who provide consent</offsets></p><p><offsets xml_i="8569" xml_f="8663" txt_i="3839" txt_f="3933">• The proportion of screened patients who are ineligible due to need for immediate transfusion</offsets></p><p><offsets xml_i="8670" xml_f="8698" txt_i="3934" txt_f="3962">• Overall protocol adherence</offsets></p><p><offsets xml_i="8705" xml_f="8737" txt_i="3963" txt_f="3995">• Protocol adherence per patient</offsets></p><p><offsets xml_i="8744" xml_f="8777" txt_i="3996" txt_f="4029">• Protocol adherence per Hb count</offsets></p><p><offsets xml_i="8784" xml_f="8874" txt_i="4030" txt_f="4120">• Baseline characteristics of consented patients (age, shock, Hb, clinical Rockall score [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="8905" xml_f="8906" txt_i="4120" txt_f="4121">9</offsets></xref><offsets xml_i="8913" xml_f="8934" txt_i="4121" txt_f="4142">], Blatchford score [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="8966" xml_f="8968" txt_i="4142" txt_f="4144">10</offsets></xref><offsets xml_i="8975" xml_f="9068" txt_i="4144" txt_f="4237">] (two commonly used risk scores), and number of major co-morbidities for consented patients)</offsets></p><p><offsets xml_i="9075" xml_f="9182" txt_i="4238" txt_f="4345">• The difference between consented vs non-consented patients for baseline Hb, Rockall and Blatchford scores</offsets></p><p><offsets xml_i="9189" xml_f="9225" txt_i="4346" txt_f="4382">• The number of RBC units transfused</offsets></p><p><offsets xml_i="9232" xml_f="9299" txt_i="4383" txt_f="4450">• The proportion of patients receiving at least one RBC transfusion</offsets></p><p><offsets xml_i="9306" xml_f="9392" txt_i="4451" txt_f="4537">• Mean Hb over the first seven days, up to discharge, and over the entire study period</offsets></p><p><offsets xml_i="9399" xml_f="9551" txt_i="4538" txt_f="4690">• Differences between consented patients and those discharged before being approached for consent in the Rockall and Blatchford scores, and baseline Hb.</offsets></p><p><offsets xml_i="9558" xml_f="9681" txt_i="4691" txt_f="4814">The intra-class correlation coefficient and its 95% confidence interval from this feasibility trial will also be presented.</offsets></p></sec><sec><title><offsets xml_i="9703" xml_f="9720" txt_i="4816" txt_f="4833">Clinical outcomes</offsets></title><p><offsets xml_i="9731" xml_f="9757" txt_i="4834" txt_f="4860">The clinical outcomes are:</offsets></p><p><offsets xml_i="9764" xml_f="9822" txt_i="4861" txt_f="4919">• Further bleeding up to Day 28 (primary clinical outcome)</offsets></p><p><offsets xml_i="9829" xml_f="9872" txt_i="4920" txt_f="4963">• Further bleeding up to hospital discharge</offsets></p><p><offsets xml_i="9879" xml_f="9913" txt_i="4964" txt_f="4998">• All-cause mortality up to Day 28</offsets></p><p><offsets xml_i="9920" xml_f="9966" txt_i="4999" txt_f="5045">• All-cause mortality up to hospital discharge</offsets></p><p><offsets xml_i="9973" xml_f="10022" txt_i="5046" txt_f="5095">• Therapeutic intervention at the index endoscopy</offsets></p><p><offsets xml_i="10029" xml_f="10113" txt_i="5096" txt_f="5180">• Surgical or radiological intervention to control bleeding up to death or discharge</offsets></p><p><offsets xml_i="10120" xml_f="10184" txt_i="5181" txt_f="5245">• Occurrence of a thromboembolic or ischaemic event up to Day 28</offsets></p><p><offsets xml_i="10191" xml_f="10267" txt_i="5246" txt_f="5322">• Occurrence of a thromboembolic or ischaemic event up to hospital discharge</offsets></p><p><offsets xml_i="10274" xml_f="10328" txt_i="5323" txt_f="5377">• Acute transfusion reactions up to death or discharge</offsets></p><p><offsets xml_i="10335" xml_f="10359" txt_i="5378" txt_f="5402">• Infection up to Day 28</offsets></p><p><offsets xml_i="10366" xml_f="10402" txt_i="5403" txt_f="5439">• Infection up to hospital discharge</offsets></p><p><offsets xml_i="10409" xml_f="10434" txt_i="5440" txt_f="5465">• Length of hospital stay</offsets></p><p><offsets xml_i="10441" xml_f="10483" txt_i="5466" txt_f="5508">• Health related quality of life at Day 28</offsets></p><p><offsets xml_i="10490" xml_f="10534" txt_i="5509" txt_f="5553">• Serious adverse events (SAEs) up to Day 28</offsets></p><p><offsets xml_i="10541" xml_f="10813" txt_i="5554" txt_f="5826">The individual components that make up the composite outcome of a thromboembolic or ischaemic event (myocardial infarction, stroke, pulmonary embolus, deep vein thrombosis, and acute kidney injury) will also be analysed separately at both Day 28 and at hospital discharge.</offsets></p></sec></sec><sec><title><offsets xml_i="10841" xml_f="10860" txt_i="5829" txt_f="5848">Analysis principles</offsets></title><sec><title><offsets xml_i="10880" xml_f="10900" txt_i="5849" txt_f="5869">Feasibility outcomes</offsets></title><p><offsets xml_i="10911" xml_f="11471" txt_i="5870" txt_f="6430">Analysis of the feasibility outcomes will be by intention-to-treat (ITT), and will include all consented patients on whom an outcome is available, unless otherwise stated. A secondary analysis will include all consented patients with a recorded Hb below 12 g/dL during follow-up, and for whom an outcome is available (this secondary analysis will be restricted to RBC transfusion outcomes, Hb concentration outcomes, and adherence outcomes). A 5% significance level will be used. All analyses of feasibility outcomes will be unadjusted for baseline covariates.</offsets></p></sec><sec><title><offsets xml_i="11493" xml_f="11510" txt_i="6432" txt_f="6449">Clinical outcomes</offsets></title><p><offsets xml_i="11521" xml_f="12441" txt_i="6450" txt_f="7367">Main analysis of the clinical outcomes will be by ITT, and will include all consented patients with a recorded Hb below 12 g/dL during follow-up, and for whom the outcome is available. Including only patients with a Hb &lt;12 g/dL allows us to target those patients most likely to be affected by the treatment policy, resulting in a more powerful analysis on a more relevant patient population. A Hb of 12 g/dL was chosen as the cut-off point because it is likely that some patients will be transfused (against policy) above 10 g/dL; if the proportion of patients transfused above 10 g/dL differs between treatment arms, excluding these patients could lead to bias. Using a cut-off of 12 g/dL should allow the majority of transfused patients to be included in the analysis, leading to an unbiased comparison. A secondary analysis will include all consented patients, regardless of whether their Hb dropped below 12 g/dL.</offsets></p><p><offsets xml_i="12448" xml_f="12983" txt_i="7368" txt_f="7897">Results will be considered statistically significant at the 5% level. Main analyses for clinical outcomes will be unadjusted for baseline covariates; however, a set of secondary analyses will be adjusted for patient age, the presence of shock, the number of major co-morbidities, and the presence of coagulopathy (defined as an international normalised ratio (INR) &gt;1.5 or a prothrombin time (PT) &gt;3 seconds greater than the control). Mean imputation within the centre will be used for patients with missing baseline covariates [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="13015" xml_f="13017" txt_i="7897" txt_f="7899">11</offsets></xref><offsets xml_i="13024" xml_f="13312" txt_i="7899" txt_f="8187">]. Patient age and the number of major co-morbidities (encompassing ischaemic heart disease, cardiac failure, liver disease, renal disease, respiratory disease, malignancy and stroke) will be modelled using fractional polynomials to allow for the possibility of a non-linear association [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="13344" xml_f="13346" txt_i="8187" txt_f="8189">12</offsets></xref><offsets xml_i="13353" xml_f="13430" txt_i="8189" txt_f="8266">]. Further bleeding up to Day 28 is regarded as the primary clinical outcome.</offsets></p></sec><sec><title><offsets xml_i="13452" xml_f="13468" txt_i="8268" txt_f="8284">Analysis methods</offsets></title><p><offsets xml_i="13479" xml_f="13583" txt_i="8285" txt_f="8389">All analyses will account for clustering to ensure correct type I error rates and confidence intervals [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="13615" xml_f="13617" txt_i="8389" txt_f="8391">13</offsets></xref><offsets xml_i="13624" xml_f="13625" txt_i="8391" txt_f="8392">-</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="13657" xml_f="13659" txt_i="8392" txt_f="8394">15</offsets></xref><offsets xml_i="13666" xml_f="14054" txt_i="8394" txt_f="8782">]. Many cluster randomised trials base their analysis on individual level patient data, and use appropriate statistical methods to account for clustering between patients in the same cluster (for example, mixed-effects models or generalised estimating equations). However, analysis methods based on individual level patient data may not perform well when the number of clusters is small [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="14086" xml_f="14088" txt_i="8782" txt_f="8784">13</offsets></xref><offsets xml_i="14095" xml_f="14096" txt_i="8784" txt_f="8785">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="14128" xml_f="14130" txt_i="8785" txt_f="8787">14</offsets></xref><offsets xml_i="14137" xml_f="14285" txt_i="8787" txt_f="8935">]. Analysis for TRIGGER will, therefore, be performed using cluster-level summaries, which performs well even with a very small number of clusters [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="14317" xml_f="14319" txt_i="8935" txt_f="8937">13</offsets></xref><offsets xml_i="14326" xml_f="14327" txt_i="8937" txt_f="8938">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="14359" xml_f="14361" txt_i="8938" txt_f="8940">14</offsets></xref><offsets xml_i="14368" xml_f="14370" txt_i="8940" txt_f="8942">].</offsets></p><p><offsets xml_i="14377" xml_f="14573" txt_i="8943" txt_f="9139">Equal weight will be given to each of the six clusters. All analyses will compare the two treatment arms, unless otherwise stated. Binary outcomes will be presented as a difference in proportions.</offsets></p></sec><sec><title><offsets xml_i="14595" xml_f="14614" txt_i="9141" txt_f="9160">Unadjusted analyses</offsets></title><p><offsets xml_i="14625" xml_f="15366" txt_i="9161" txt_f="9902">Unadjusted analyses using cluster-level summaries can be performed by calculating a summary outcome from each centre, and fitting a linear regression model with the summary outcome as a response variable, and treatment arm as a covariate. For example, for the outcome of mortality, one might choose the proportion of patients who died as a summary measure. To perform the analysis, one would then need to calculate the proportion of patients who died in each centre. A linear regression model would then be fitted, with the proportion of patients who died in each centre as the outcome, and which treatment the centre was randomised to as a covariate (in the TRIGGER trial there would only be six data points, as there are only six centres).</offsets></p></sec><sec><title><offsets xml_i="15388" xml_f="15405" txt_i="9904" txt_f="9921">Adjusted analyses</offsets></title><p><offsets xml_i="15416" xml_f="15494" txt_i="9922" txt_f="10000">Adjusted analyses using cluster-level summaries will be performed as follows [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="15526" xml_f="15528" txt_i="10000" txt_f="10002">14</offsets></xref><offsets xml_i="15535" xml_f="15537" txt_i="10002" txt_f="10004">]:</offsets></p><p><offsets xml_i="15544" xml_f="15888" txt_i="10005" txt_f="10349">1) A regression model (linear for continuous outcomes and logistic for binary outcomes) will be fit to individual-level patient data, and will be adjusted for the baseline characteristics listed earlier (age, shock, presence of coagulopathy and the number of major co-morbidities). The model will not adjust for treatment effect, or for centre.</offsets></p><p><offsets xml_i="15895" xml_f="16137" txt_i="10350" txt_f="10592">2) Predicted values based on the fitted regression model will be calculated for each patient (for binary outcomes this equates to the predicted probability of experiencing an event, for continuous outcomes this equates to the predicted mean).</offsets></p><p><offsets xml_i="16144" xml_f="16493" txt_i="10593" txt_f="10942">3) The expected outcome in each cluster will be calculated. For binary outcomes, this is the expected number of events in each cluster, and is calculated by summing the predicted probabilities for each patient in that cluster. For continuous outcomes, the expected mean value is calculated by taking the mean of the predicted values in each cluster.</offsets></p><p><offsets xml_i="16500" xml_f="16780" txt_i="10943" txt_f="11223">4) An appropriate residual is calculated for each cluster. For binary outcomes, this is the observed number of events minus the expected number of events, divided by the number of patients in the cluster. For continuous outcomes, this is the observed mean minus the expected mean.</offsets></p><p><offsets xml_i="16787" xml_f="17075" txt_i="11224" txt_f="11512">5) A linear regression model will be fit using the residuals calculated above as cluster-level summaries, with only the treatment group as a covariate. No degrees of freedom correction will be made for performing an adjusted analysis, as only patient-level variables will be adjusted for.</offsets></p></sec><sec><title><offsets xml_i="17097" xml_f="17145" txt_i="11514" txt_f="11562">Cluster level summaries for feasibility outcomes</offsets></title><p><offsets xml_i="17156" xml_f="17261" txt_i="11563" txt_f="11668">Cluster-level summaries for feasibility outcomes will be calculated separately in each centre as follows:</offsets></p><p><offsets xml_i="17268" xml_f="17271" txt_i="11669" txt_f="11672">1) </offsets><bold><offsets xml_i="17277" xml_f="17316" txt_i="11672" txt_f="11711">Recruitment rate (patients consenting):</offsets></bold><offsets xml_i="17323" xml_f="17378" txt_i="11711" txt_f="11766"> the proportion of eligible patients providing consent.</offsets></p><p><offsets xml_i="17385" xml_f="17388" txt_i="11767" txt_f="11770">2) </offsets><bold><offsets xml_i="17394" xml_f="17433" txt_i="11770" txt_f="11809">Ineligible due to severity of bleeding:</offsets></bold><offsets xml_i="17440" xml_f="17523" txt_i="11809" txt_f="11892"> the proportion of screened patients who are ineligible due to severity of bleeding</offsets></p><p><offsets xml_i="17530" xml_f="17533" txt_i="11893" txt_f="11896">3) </offsets><bold><offsets xml_i="17539" xml_f="17557" txt_i="11896" txt_f="11914">Overall adherence:</offsets></bold><offsets xml_i="17564" xml_f="17600" txt_i="11914" txt_f="11950"> the mean adherence rate per patient</offsets></p><p><offsets xml_i="17607" xml_f="17610" txt_i="11951" txt_f="11954">4) </offsets><bold><offsets xml_i="17616" xml_f="17638" txt_i="11954" txt_f="11976">Adherence per patient:</offsets></bold><offsets xml_i="17645" xml_f="17703" txt_i="11976" txt_f="12034"> the proportion of patients who had no protocol deviations</offsets></p><p><offsets xml_i="17710" xml_f="17713" txt_i="12035" txt_f="12038">5) </offsets><bold><offsets xml_i="17719" xml_f="17742" txt_i="12038" txt_f="12061">Adherence per Hb count:</offsets></bold><offsets xml_i="17749" xml_f="17819" txt_i="12061" txt_f="12131"> the proportion of Hb counts that did not lead to a protocol deviation</offsets></p><p><offsets xml_i="17826" xml_f="17829" txt_i="12132" txt_f="12135">6) </offsets><bold><offsets xml_i="17835" xml_f="17894" txt_i="12135" txt_f="12194">Selection bias - baseline variables for consented patients:</offsets></bold><offsets xml_i="17901" xml_f="18090" txt_i="12194" txt_f="12383"> The mean age, baseline Hb, number of major co-morbidities, clinical Rockall score and Blatchford score, and the proportion of patients with shock will be calculated for consented patients.</offsets></p><p><offsets xml_i="18097" xml_f="18100" txt_i="12384" txt_f="12387">7) </offsets><bold><offsets xml_i="18106" xml_f="18201" txt_i="12387" txt_f="12482">Selection bias - difference between consented and non-consented patients in baseline variables:</offsets></bold><offsets xml_i="18208" xml_f="18372" txt_i="12482" txt_f="12646"> The difference in the mean Rockall score and Blatchford score, and mean baseline Hb between consented and non-consented patients will be calculated in each centre.</offsets></p><p><offsets xml_i="18379" xml_f="18382" txt_i="12647" txt_f="12650">8) </offsets><bold><offsets xml_i="18388" xml_f="18437" txt_i="12650" txt_f="12699">Red blood cell exposure (number of transfusions):</offsets></bold><offsets xml_i="18444" xml_f="18497" txt_i="12699" txt_f="12752"> the mean number of RBC units transfused per patient.</offsets></p><p><offsets xml_i="18504" xml_f="18507" txt_i="12753" txt_f="12756">9) </offsets><bold><offsets xml_i="18513" xml_f="18583" txt_i="12756" txt_f="12826">Red blood cell exposure (patients receiving at least one transfusion):</offsets></bold><offsets xml_i="18590" xml_f="18659" txt_i="12826" txt_f="12895"> the proportion of patients who receive at least one RBC transfusion.</offsets></p><p><offsets xml_i="18666" xml_f="18670" txt_i="12896" txt_f="12900">10) </offsets><bold><offsets xml_i="18676" xml_f="18787" txt_i="12900" txt_f="13011">Hb concentration up to Day 7, and over the entire in-hospital follow-up period, prior to discharge/death/Day28:</offsets></bold><offsets xml_i="18794" xml_f="18855" txt_i="13011" txt_f="13072"> the area-under-the-curve will be calculated for each patient</offsets></p><p><offsets xml_i="18862" xml_f="18866" txt_i="13073" txt_f="13077">11) </offsets><bold><offsets xml_i="18872" xml_f="18902" txt_i="13077" txt_f="13107">Hb concentration at discharge:</offsets></bold><offsets xml_i="18909" xml_f="18940" txt_i="13107" txt_f="13138"> the mean Hb will be calculated</offsets></p></sec><sec><title><offsets xml_i="18962" xml_f="19007" txt_i="13140" txt_f="13185">Cluster level summaries for clinical outcomes</offsets></title><p><offsets xml_i="19018" xml_f="19460" txt_i="13186" txt_f="13628">The cluster-level summary will be calculated as the proportion of patients in each centre experiencing the event of interest for the following outcomes: further bleeding, all-cause mortality, need for therapeutic intervention at index endoscopy, need for surgery or radiological intervention to control bleeding, any thromboembolic or ischaemic events (and each of the components separately), acute transfusion reactions, infections and SAEs.</offsets></p><p><offsets xml_i="19467" xml_f="19690" txt_i="13629" txt_f="13852">A cluster-level summary for length of hospital stay will be calculated using the median length of stay in each centre, and a cluster-level summary for health related quality of life will be calculated using the mean EQ-5D [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="19722" xml_f="19724" txt_i="13852" txt_f="13854">16</offsets></xref><offsets xml_i="19731" xml_f="19748" txt_i="13854" txt_f="13871">] in each centre.</offsets></p></sec><sec><title><offsets xml_i="19770" xml_f="19787" txt_i="13873" txt_f="13890">Subgroup analyses</offsets></title><p><offsets xml_i="19798" xml_f="20048" txt_i="13891" txt_f="14141">Subgroup analyses will be performed for two outcomes: further bleeding and all-cause mortality (both up to Day 28) using an interaction test, and considered statistically significant at the 5% level. The following subgroup analyses will be performed:</offsets></p><p><offsets xml_i="20055" xml_f="20091" txt_i="14142" txt_f="14178">• Variceal vs. non-variceal bleeding</offsets></p><p><offsets xml_i="20098" xml_f="20154" txt_i="14179" txt_f="14235">• Ischaemic heart disease vs. no ischaemic heart disease</offsets></p><p><offsets xml_i="20161" xml_f="20305" txt_i="14236" txt_f="14380">Interaction tests will be performed by calculating the difference in proportions (for the chosen outcome) between subgroups within each centre [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="20337" xml_f="20339" txt_i="14380" txt_f="14382">14</offsets></xref><offsets xml_i="20346" xml_f="20606" txt_i="14382" txt_f="14642">]. A linear regression model will then be fit, with the difference in proportions between subgroups as the outcome, and treatment as a covariate. Interaction tests will be unadjusted for baseline covariates, and will be reported with a 95% confidence interval.</offsets></p></sec><sec><title><offsets xml_i="20628" xml_f="20648" txt_i="14644" txt_f="14664">Sensitivity analyses</offsets></title><p><offsets xml_i="20659" xml_f="20965" txt_i="14665" txt_f="14971">Missing data for each clinical outcome will be summarised by treatment arm. Sensitivity to missing data for further bleeding and all-cause mortality up to Day 28 will be assessed under a range of missing-not-at-random scenarios. This will be done by calculating the mean outcome in each cluster as follows:</offsets></p><p><disp-formula><mml:math id="M1" name="1745-6215-14-206-i1" overflow="scroll"><mml:mrow><mml:mfenced open="(" close=")"><mml:msub><mml:mi><offsets xml_i="21109" xml_f="21110" txt_i="14972" txt_f="14973">x</offsets></mml:mi><mml:mi mathvariant="italic"><offsets xml_i="21148" xml_f="21151" txt_i="14973" txt_f="14976">obs</offsets></mml:mi></mml:msub></mml:mfenced><mml:mfenced open="(" close=")"><mml:mrow><mml:mn><offsets xml_i="21235" xml_f="21236" txt_i="14976" txt_f="14977">1</offsets></mml:mn><mml:mo><offsets xml_i="21253" xml_f="21254" txt_i="14977" txt_f="14978">−</offsets></mml:mo><mml:msub><mml:mi mathvariant="italic"><offsets xml_i="21302" xml_f="21303" txt_i="14978" txt_f="14979">p</offsets></mml:mi><mml:mi mathvariant="italic"><offsets xml_i="21341" xml_f="21348" txt_i="14979" txt_f="14986">missing</offsets></mml:mi></mml:msub></mml:mrow></mml:mfenced><mml:mo><offsets xml_i="21401" xml_f="21402" txt_i="14986" txt_f="14987">+</offsets></mml:mo><mml:mfenced open="(" close=")"><mml:msub><mml:mi><offsets xml_i="21461" xml_f="21462" txt_i="14987" txt_f="14988">x</offsets></mml:mi><mml:mi mathvariant="italic"><offsets xml_i="21500" xml_f="21511" txt_i="14988" txt_f="14999">sensitivity</offsets></mml:mi></mml:msub></mml:mfenced><mml:mfenced open="(" close=")"><mml:msub><mml:mi mathvariant="italic"><offsets xml_i="21616" xml_f="21617" txt_i="14999" txt_f="15000">p</offsets></mml:mi><mml:mi mathvariant="italic"><offsets xml_i="21655" xml_f="21662" txt_i="15000" txt_f="15007">missing</offsets></mml:mi></mml:msub></mml:mfenced></mml:mrow></mml:math></disp-formula></p><p><offsets xml_i="21740" xml_f="21746" txt_i="15008" txt_f="15014">where </offsets><italic><offsets xml_i="21754" xml_f="21755" txt_i="15014" txt_f="15015">x</offsets></italic><sub><italic><offsets xml_i="21777" xml_f="21780" txt_i="15015" txt_f="15018">obs</offsets></italic></sub><offsets xml_i="21795" xml_f="21835" txt_i="15018" txt_f="15058"> is the observed cluster level summary, </offsets><italic><offsets xml_i="21843" xml_f="21844" txt_i="15058" txt_f="15059">p</offsets></italic><sub><italic><offsets xml_i="21866" xml_f="21873" txt_i="15059" txt_f="15066">missing</offsets></italic></sub><offsets xml_i="21888" xml_f="21958" txt_i="15066" txt_f="15136"> is the proportion of patients with missing data in that cluster, and </offsets><italic><offsets xml_i="21966" xml_f="21967" txt_i="15136" txt_f="15137">x</offsets></italic><sub><italic><offsets xml_i="21989" xml_f="22000" txt_i="15137" txt_f="15148">sensitivity</offsets></italic></sub><offsets xml_i="22015" xml_f="22115" txt_i="15148" txt_f="15248"> is the proportion of patients with missing data who are assumed to have had the event of interest. </offsets><italic><offsets xml_i="22123" xml_f="22124" txt_i="15248" txt_f="15249">x</offsets></italic><sub><italic><offsets xml_i="22146" xml_f="22157" txt_i="15249" txt_f="15260">sensitivity</offsets></italic></sub><offsets xml_i="22172" xml_f="22303" txt_i="15260" txt_f="15391"> will be varied between 0, 0.2, 0.4, 0.6, 0.8 and 1. The treatment effect and 95% confidence interval will be calculated as before.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="22353" xml_f="22363" txt_i="15394" txt_f="15404">Discussion</offsets></title><p><offsets xml_i="22374" xml_f="22636" txt_i="15405" txt_f="15667">It has become increasingly common in recent years to prospectively publish trial protocols to increase transparency by allowing a comparison between what was presented in the final manuscript and what was planned in the protocol before trial results were known [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="22668" xml_f="22670" txt_i="15667" txt_f="15669">17</offsets></xref><offsets xml_i="22677" xml_f="22678" txt_i="15669" txt_f="15670">-</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="22710" xml_f="22712" txt_i="15670" txt_f="15672">20</offsets></xref><offsets xml_i="22719" xml_f="22824" txt_i="15672" txt_f="15777">]. The rationale for prospectively publishing trial protocols also applies to statistical analysis plans.</offsets></p><p><offsets xml_i="22831" xml_f="23011" txt_i="15778" txt_f="15958">There are generally a number of different ways to analyse an outcome in a clinical trial. For example, analyses could adjust for different covariates, or be completely unadjusted [</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="23043" xml_f="23045" txt_i="15958" txt_f="15960">21</offsets></xref><offsets xml_i="23052" xml_f="23053" txt_i="15960" txt_f="15961">-</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="23085" xml_f="23087" txt_i="15961" txt_f="15963">24</offsets></xref><offsets xml_i="23094" xml_f="23297" txt_i="15963" txt_f="16166">]; if covariates were adjusted for in the analysis, this could be performed in different ways (for example, using Mantel-Haenszel estimates, or an adjusted logistic regression model for binary outcomes [</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="23329" xml_f="23331" txt_i="16166" txt_f="16168">25</offsets></xref><offsets xml_i="23338" xml_f="23504" txt_i="16168" txt_f="16334">]). In multicentre trials, one could either ignore the centre-effects, or account for them in a number of different ways (for example, using fixed or random effects [</offsets><xref ref-type="bibr" rid="B26"><offsets xml_i="23536" xml_f="23538" txt_i="16334" txt_f="16336">26</offsets></xref><offsets xml_i="23545" xml_f="23546" txt_i="16336" txt_f="16337">-</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="23578" xml_f="23580" txt_i="16337" txt_f="16339">28</offsets></xref><offsets xml_i="23587" xml_f="23816" txt_i="16339" txt_f="16568">]). Issues regarding multiplicity (for example, when taking multiple looks at the data through interim analyses, or through multiple pairwise comparisons between treatment groups) may or may not be accounted for in the analysis [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="23848" xml_f="23850" txt_i="16568" txt_f="16570">29</offsets></xref><offsets xml_i="23857" xml_f="23859" txt_i="16570" txt_f="16572">].</offsets></p><p><offsets xml_i="23866" xml_f="24349" txt_i="16573" txt_f="17056">It is hoped that results will be robust, and will give similar conclusions regardless of the method of analysis used. However, different analysis methods will often give different results, either through chance or because some analysis methods are more appropriate in certain situations. It is important for trialists to pre-specify the method of analysis to prevent them from assessing the data using several different methods of analysis, and presenting the most favourable result.</offsets></p><p><offsets xml_i="24356" xml_f="24481" txt_i="17057" txt_f="17182">The benefits from a prospectively published statistical analysis plan can be seen from a randomised trial published in 2013 [</offsets><xref ref-type="bibr" rid="B30"><offsets xml_i="24513" xml_f="24515" txt_i="17182" txt_f="17184">30</offsets></xref><offsets xml_i="24522" xml_f="24721" txt_i="17184" txt_f="17383">]. The trial used a group sequential design, which is known to lead to biased estimates of treatment effect and inflated type I error rates if it is not properly accounted for in the trial analysis [</offsets><xref ref-type="bibr" rid="B29"><offsets xml_i="24753" xml_f="24755" txt_i="17383" txt_f="17385">29</offsets></xref><offsets xml_i="24762" xml_f="25284" txt_i="17385" txt_f="17907">]. In this trial, accounting for the group sequential nature of the trial would have given a non-significant result for the primary outcome, whereas ignoring it gave a statistically significant result. The manuscript presented the significant result as their primary analysis; had the statistical analysis plan been prospectively published prior to data analysis it would have given readers more confidence that the method of analysis had not been chosen based on whether or not it gave a statistically significant result.</offsets></p><p><offsets xml_i="25291" xml_f="25722" txt_i="17908" txt_f="18339">We are, therefore, prospectively publishing the statistical analysis plan for the TRIGGER trial to increase transparency, and to provide readers with a more complete picture of the methods that will be used to analyse the trial. The statistical analysis plan was signed off in February 2013, before any trial investigators had access to the trial database. Recruitment to TRIGGER began in September 2012 and finished in March 2013.</offsets></p></sec><sec><title><offsets xml_i="25744" xml_f="25757" txt_i="18341" txt_f="18354">Abbreviations</offsets></title><p><offsets xml_i="25768" xml_f="26020" txt_i="18355" txt_f="18607">AUGIB: Acute upper gastrointestinal bleeding; Hb: Haemoglobin; INR: International normalised ratio; ITT: Intention-to-treat; PT: Prothrombin time; RBC: Red blood cell; SAE: Serious adverse event; TRIGGER: Transfusion in gastrointestinal bleeding trial.</offsets></p></sec><sec><title><offsets xml_i="26042" xml_f="26061" txt_i="18609" txt_f="18628">Competing interests</offsets></title><p><offsets xml_i="26072" xml_f="26130" txt_i="18629" txt_f="18687">The authors declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="26152" xml_f="26174" txt_i="18689" txt_f="18711">Authors’ contributions</offsets></title><p><offsets xml_i="26185" xml_f="26348" txt_i="18712" txt_f="18875">BK wrote the initial draft of the manuscript. VJ, CD and MM provided important input into the manuscript. All authors approved the final version of the manuscript.</offsets></p></sec></body><back><sec><title>Acknowledgements</title><p>We would like to thank members of the Trial Management group (Ana Mora, James Martin, Alasdair Gray, Tim Walsh, Elizabeth Stokes, Adrian Stanley, Claire Dyer, Renate Hodge, Charlotte Llewelyn, Simon Travis, Richard Logan, Kel Palmer), the Independent Data Monitoring Committee (Michael Greaves, Bob Walt, Marc Turner and Keith Wheatley), and the chair of the Trial Steering Committee (Chris Hawkey) for their review of the trial statistical analysis plan. We would also like to thank the referee, whose comments helped to improve the clarity of the manuscript. Trial funding was awarded by the NHS Blood and Transplant R&amp;D Committee through open competition and two-stage external peer review, grant number 10-09-CSU.</p></sec><sec><title>List of recruiting centres</title><p>Edinburgh Royal Infirmary - Dr Alasdair Gray, Dr Nick Church</p><p>Glasgow Royal Infirmary - Dr Adrian Stanley</p><p>St James Hospital Leeds - Dr Simon Everett</p><p>James Cook Hospital Middlesbrough - Dr Helen Dallal, Dr John Greenaway</p><p>Queens Medical Centre Nottingham - Dr Martin James, Dr Ivan Le Jeune</p><p>Oxford University Hospital - Dr Adam Bailey, Dr Melanie Darwent and Dr Ian Reckless</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Rockall</surname><given-names>TA</given-names></name><name><surname>Logan</surname><given-names>RF</given-names></name><name><surname>Devlin</surname><given-names>HB</given-names></name><name><surname>Northfield</surname><given-names>TC</given-names></name><article-title>Incidence of and mortality from acute upper gastrointestinal haemorrhage in the united kingdom. Steering committee and members of the national audit of acute upper gastrointestinal haemorrhage</article-title><source>BMJ</source><year>1995</year><volume>311</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1136/bmj.311.6999.222</pub-id><pub-id pub-id-type="pmid">7627034</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Wallis</surname><given-names>JP</given-names></name><name><surname>Wells</surname><given-names>AW</given-names></name><name><surname>Chapman</surname><given-names>CE</given-names></name><article-title>Changing indications for red cell transfusion from 2000 to 2004 in the North of England</article-title><source>Transfus Med</source><year>2006</year><volume>16</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3148.2006.00702.x</pub-id><pub-id pub-id-type="pmid">17163872</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Hearnshaw</surname><given-names>SA</given-names></name><name><surname>Logan</surname><given-names>RF</given-names></name><name><surname>Lowe</surname><given-names>D</given-names></name><name><surname>Travis</surname><given-names>SP</given-names></name><name><surname>Murphy</surname><given-names>MF</given-names></name><name><surname>Palmer</surname><given-names>KR</given-names></name><article-title>Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit</article-title><source>Gut</source><year>2011</year><volume>60</volume><fpage>1327</fpage><lpage>1335</lpage><pub-id pub-id-type="doi">10.1136/gut.2010.228437</pub-id><pub-id pub-id-type="pmid">21490373</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Jairath</surname><given-names>V</given-names></name><name><surname>Kahan</surname><given-names>BC</given-names></name><name><surname>Logan</surname><given-names>RF</given-names></name><name><surname>Travis</surname><given-names>SP</given-names></name><name><surname>Palmer</surname><given-names>KR</given-names></name><name><surname>Murphy</surname><given-names>MF</given-names></name><article-title>Red blood cell transfusion practice in patients presenting with acute upper gastrointestinal bleeding: a survey of 815 UK clinicians</article-title><source>Transfusion</source><year>2011</year><volume>51</volume><fpage>1940</fpage><lpage>1948</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2011.03119.x</pub-id><pub-id pub-id-type="pmid">21585395</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Hearnshaw</surname><given-names>SA</given-names></name><name><surname>Logan</surname><given-names>RF</given-names></name><name><surname>Palmer</surname><given-names>KR</given-names></name><name><surname>Card</surname><given-names>TR</given-names></name><name><surname>Travis</surname><given-names>SP</given-names></name><name><surname>Murphy</surname><given-names>MF</given-names></name><article-title>Outcomes following early red blood cell transfusion in acute upper gastrointestinal bleeding</article-title><source>Aliment Pharmacol Ther</source><year>2010</year><volume>32</volume><fpage>215</fpage><lpage>224</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2010.04348.x</pub-id><pub-id pub-id-type="pmid">20456308</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Restellini</surname><given-names>S</given-names></name><name><surname>Kherad</surname><given-names>O</given-names></name><name><surname>Jairath</surname><given-names>V</given-names></name><name><surname>Martel</surname><given-names>M</given-names></name><name><surname>Barkun</surname><given-names>AN</given-names></name><article-title>Red blood cell transfusion is associated with increased rebleeding in patients with nonvariceal upper gastrointestinal bleeding</article-title><source>Aliment Pharmacol Ther</source><year>2013</year><volume>37</volume><fpage>316</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1111/apt.12170</pub-id><pub-id pub-id-type="pmid">23205554</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Villanueva</surname><given-names>C</given-names></name><name><surname>Colomo</surname><given-names>A</given-names></name><name><surname>Bosch</surname><given-names>A</given-names></name><name><surname>Concepcion</surname><given-names>M</given-names></name><name><surname>Hernandez-Gea</surname><given-names>V</given-names></name><name><surname>Aracil</surname><given-names>C</given-names></name><name><surname>Graupera</surname><given-names>I</given-names></name><name><surname>Poca</surname><given-names>M</given-names></name><name><surname>Alvarez-Urturi</surname><given-names>C</given-names></name><name><surname>Gordillo</surname><given-names>J</given-names></name><name><surname>Guarner-Argente</surname><given-names>C</given-names></name><name><surname>Santalo</surname><given-names>M</given-names></name><name><surname>Muniz</surname><given-names>E</given-names></name><name><surname>Guarner</surname><given-names>C</given-names></name><article-title>Transfusion strategies for acute upper gastrointestinal bleeding</article-title><source>N Engl J Med</source><year>2013</year><volume>368</volume><fpage>11</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1211801</pub-id><pub-id pub-id-type="pmid">23281973</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="other"><name><surname>Jairath</surname><given-names>V</given-names></name><name><surname>Kahan</surname><given-names>BC</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Doré</surname><given-names>CJ</given-names></name><name><surname>Mora</surname><given-names>A</given-names></name><name><surname>Dyer</surname><given-names>C</given-names></name><name><surname>Stokes</surname><given-names>EA</given-names></name><name><surname>Llewelyn</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>AA</given-names></name><name><surname>Dallal</surname><given-names>H</given-names></name><name><surname>Everett</surname><given-names>SM</given-names></name><name><surname>James</surname><given-names>MW</given-names></name><name><surname>Stanley</surname><given-names>AJ</given-names></name><name><surname>Church</surname><given-names>N</given-names></name><name><surname>Darwent</surname><given-names>M</given-names></name><name><surname>Greenaway</surname><given-names>J</given-names></name><name><surname>Le Jeune</surname><given-names>I</given-names></name><name><surname>Reckless</surname><given-names>I</given-names></name><name><surname>Campbell</surname><given-names>HE</given-names></name><name><surname>Meredith</surname><given-names>S</given-names></name><name><surname>Palmer</surname><given-names>KR</given-names></name><name><surname>Logan</surname><given-names>RF</given-names></name><name><surname>Travis</surname><given-names>SP</given-names></name><name><surname>Walsh</surname><given-names>TS</given-names></name><name><surname>Murphy</surname><given-names>MF</given-names></name><article-title>Restrictive vs liberal blood transfusion for. rationale and protocol for a cluster randomized feasibility trial</article-title><source>Transfus Med Rev</source><year>2013</year><comment>Epub ahead of print</comment></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Rockall</surname><given-names>TA</given-names></name><name><surname>Logan</surname><given-names>RF</given-names></name><name><surname>Devlin</surname><given-names>HB</given-names></name><name><surname>Northfield</surname><given-names>TC</given-names></name><article-title>Risk assessment after acute upper gastrointestinal haemorrhage</article-title><source>Gut</source><year>1996</year><volume>38</volume><fpage>316</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1136/gut.38.3.316</pub-id><pub-id pub-id-type="pmid">8675081</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Blatchford</surname><given-names>O</given-names></name><name><surname>Murray</surname><given-names>WR</given-names></name><name><surname>Blatchford</surname><given-names>M</given-names></name><article-title>A risk score to predict need for treatment for upper-gastrointestinal haemorrhage</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>1318</fpage><lpage>1321</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02816-6</pub-id><pub-id pub-id-type="pmid">11073021</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>White</surname><given-names>IR</given-names></name><name><surname>Thompson</surname><given-names>SG</given-names></name><article-title>Adjusting for partially missing baseline measurements in randomized trials</article-title><source>Stat Med</source><year>2005</year><volume>24</volume><fpage>993</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1002/sim.1981</pub-id><pub-id pub-id-type="pmid">15570623</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="book"><name><surname>Royston</surname><given-names>P</given-names></name><name><surname>Sauerbrei</surname><given-names>W</given-names></name><source>Multivariable Model-Building: A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables</source><year>2008</year><publisher-name>Chichester UK: Wiley</publisher-name></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="book"><name><surname>Donner</surname><given-names>A</given-names></name><name><surname>Klar</surname><given-names>N</given-names></name><source>Design and Analysis of Cluster Randomization Trials in Health Research</source><year>2000</year><publisher-name>New York: Oxford University Press Inc.</publisher-name></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="book"><name><surname>Hayes</surname><given-names>RJ</given-names></name><name><surname>Moulton</surname><given-names>LH</given-names></name><source>Cluster Randomised Trials</source><year>2009</year><publisher-name>Boca Raton, FL: Chapman &amp; Hall/CRC</publisher-name></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kahan</surname><given-names>BC</given-names></name><name><surname>Morris</surname><given-names>TP</given-names></name><article-title>Assessing potential sources of clustering in individually randomised trials</article-title><source>BMC Med Res Methodol</source><year>2013</year><volume>13</volume><fpage>58</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-13-58</pub-id><pub-id pub-id-type="pmid">23590245</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><article-title>EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group</article-title><source>Health Policy</source><year>1990</year><volume>16</volume><fpage>199</fpage><lpage>208</lpage><pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Gotzsche</surname><given-names>PC</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Mann</surname><given-names>H</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Dickersin</surname><given-names>K</given-names></name><name><surname>Hróbjartsson</surname><given-names>A</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Parulekar</surname><given-names>WR</given-names></name><name><surname>Krleza-Jeric</surname><given-names>K</given-names></name><name><surname>Laupacis</surname><given-names>A</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><article-title>SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials</article-title><source>BMJ</source><year>2013</year><volume>346</volume><fpage>e7586</fpage><pub-id pub-id-type="doi">10.1136/bmj.e7586</pub-id><pub-id pub-id-type="pmid">23303884</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Dwan</surname><given-names>K</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Arnaiz</surname><given-names>JA</given-names></name><name><surname>Bloom</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Cronin</surname><given-names>E</given-names></name><name><surname>Decullier</surname><given-names>E</given-names></name><name><surname>Easterbrook</surname><given-names>PJ</given-names></name><name><surname>Von Elm</surname><given-names>E</given-names></name><name><surname>Gamble</surname><given-names>C</given-names></name><name><surname>Ghersi</surname><given-names>D</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>Simes</surname><given-names>J</given-names></name><name><surname>Williamson</surname><given-names>PR</given-names></name><article-title>Systematic review of the empirical evidence of study publication bias and outcome reporting bias</article-title><source>PLoS One</source><year>2008</year><volume>3</volume><fpage>e3081</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0003081</pub-id><pub-id pub-id-type="pmid">18769481</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="other"><name><surname>Dwan</surname><given-names>K</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Cresswell</surname><given-names>L</given-names></name><name><surname>Blundell</surname><given-names>M</given-names></name><name><surname>Gamble</surname><given-names>CL</given-names></name><name><surname>Williamson</surname><given-names>PR</given-names></name><article-title>Comparison of protocols and registry entries to published reports for randomised controlled trials</article-title><source>Cochrane Database Syst Rev</source><year>2011</year><fpage>MR000031</fpage><pub-id pub-id-type="pmid">21249714</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Rising</surname><given-names>K</given-names></name><name><surname>Bacchetti</surname><given-names>P</given-names></name><name><surname>Bero</surname><given-names>L</given-names></name><article-title>Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation</article-title><source>PLoS Med</source><year>2008</year><volume>5</volume><fpage>e217</fpage><comment>discussion e217</comment><pub-id pub-id-type="doi">10.1371/journal.pmed.0050217</pub-id><pub-id pub-id-type="pmid">19067477</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Hernandez</surname><given-names>AV</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><name><surname>Habbema</surname><given-names>JD</given-names></name><article-title>Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements</article-title><source>J Clin Epidemiol</source><year>2004</year><volume>57</volume><fpage>454</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2003.09.014</pub-id><pub-id pub-id-type="pmid">15196615</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Kahan</surname><given-names>BC</given-names></name><name><surname>Morris</surname><given-names>TP</given-names></name><article-title>Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysis</article-title><source>BMJ</source><year>2012</year><volume>345</volume><fpage>e5840</fpage><pub-id pub-id-type="doi">10.1136/bmj.e5840</pub-id><pub-id pub-id-type="pmid">22983531</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Turner</surname><given-names>EL</given-names></name><name><surname>Perel</surname><given-names>P</given-names></name><name><surname>Clayton</surname><given-names>T</given-names></name><name><surname>Edwards</surname><given-names>P</given-names></name><name><surname>Hernandez</surname><given-names>AV</given-names></name><name><surname>Roberts</surname><given-names>I</given-names></name><name><surname>Shakur</surname><given-names>H</given-names></name><name><surname>Steyerberg</surname><given-names>EW</given-names></name><article-title>Covariate adjustment increased power in randomized controlled trials: an example in traumatic brain injury</article-title><source>J Clin Epidemiol</source><year>2012</year><volume>65</volume><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2011.08.012</pub-id><pub-id pub-id-type="pmid">22169080</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Kahan</surname><given-names>BC</given-names></name><name><surname>Morris</surname><given-names>TP</given-names></name><article-title>Improper analysis of trials randomised using stratified blocks or minimisation</article-title><source>Stat Med</source><year>2012</year><volume>31</volume><fpage>328</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1002/sim.4431</pub-id><pub-id pub-id-type="pmid">22139891</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Agresti</surname><given-names>A</given-names></name><name><surname>Hartzel</surname><given-names>J</given-names></name><article-title>Strategies for comparing treatments on a binary response with multi-centre data</article-title><source>Stat Med</source><year>2000</year><volume>19</volume><fpage>1115</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0258(20000430)19:8&lt;1115::AID-SIM408&gt;3.0.CO;2-X</pub-id><pub-id pub-id-type="pmid">10790684</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Pickering</surname><given-names>RM</given-names></name><name><surname>Weatherall</surname><given-names>M</given-names></name><article-title>The analysis of continuous outcomes in multi-centre trials with small centre sizes</article-title><source>Stat Med</source><year>2007</year><volume>26</volume><fpage>5445</fpage><lpage>5456</lpage><pub-id pub-id-type="doi">10.1002/sim.3068</pub-id><pub-id pub-id-type="pmid">17924360</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Chu</surname><given-names>R</given-names></name><name><surname>Thabane</surname><given-names>L</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Holbrook</surname><given-names>A</given-names></name><name><surname>Pullenayegum</surname><given-names>E</given-names></name><name><surname>Devereaux</surname><given-names>PJ</given-names></name><article-title>Comparing methods to estimate treatment effects on a continuous outcome in multicentre randomized controlled trials: a simulation study</article-title><source>BMC Med Res Methodol</source><year>2011</year><volume>11</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/1471-2288-11-21</pub-id><pub-id pub-id-type="pmid">21338524</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Kahan</surname><given-names>BC</given-names></name><name><surname>Morris</surname><given-names>TP</given-names></name><article-title>Analysis of multicentre trials with continuous outcomes: when and how should we account for centre effects?</article-title><source>Stat Med</source><year>2013</year><volume>32</volume><fpage>1136</fpage><lpage>1149</lpage><pub-id pub-id-type="doi">10.1002/sim.5667</pub-id><pub-id pub-id-type="pmid">23112128</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="book"><name><surname>Jennison</surname><given-names>C</given-names></name><name><surname>Turnbull</surname><given-names>BW</given-names></name><source>Group Sequential Methods with Applications to Clinical Trials</source><year>2000</year><publisher-name>Boca Raton, FL: Chapman &amp; Hall/CRC Interdisciplinary Statistics</publisher-name></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Howard</surname><given-names>J</given-names></name><name><surname>Malfroy</surname><given-names>M</given-names></name><name><surname>Llewelyn</surname><given-names>C</given-names></name><name><surname>Choo</surname><given-names>L</given-names></name><name><surname>Hodge</surname><given-names>R</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Purohit</surname><given-names>S</given-names></name><name><surname>Rees</surname><given-names>DC</given-names></name><name><surname>Tillyer</surname><given-names>L</given-names></name><name><surname>Walker</surname><given-names>I</given-names></name><name><surname>Fijnvandraat</surname><given-names>K</given-names></name><name><surname>Kirby-Allen</surname><given-names>M</given-names></name><name><surname>Spackman</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>SC</given-names></name><name><surname>Williamson</surname><given-names>LM</given-names></name><article-title>The transfusion alternatives preoperatively in sickle cell disease (TAPS) study: a randomised, controlled, multicentre clinical trial</article-title><source>Lancet</source><year>2013</year><volume>381</volume><fpage>930</fpage><lpage>938</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61726-7</pub-id><pub-id pub-id-type="pmid">23352054</pub-id></mixed-citation></ref></ref-list></back></article>